A New Vaccine, a Novel Coronavirus

6min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Moderna had been quietly overseeing a revolution in mRNA technology. They'd built a platform model for drug treatments and vaccines. Stefan knew this platform had great potential, but in early 2020 it was relatively untested. Moderna's platform was tailor made respond quickly to a pathogen like coronavirus. But putting that vaccine into production so that it would be ready to roll out if the Wuhan outbreak became a pandemic would be a huge upheaval and risk for the company.

Taking risks can be the catalyst for immense scale or dire straits. Avoiding taking any risks at all leads to stagnancy and empowered competitors. The key is to know which risks are worth taking, and when and how to take them. This episode highlights the best conversations we’ve had recently about taking advantage of risk and how fortune favors the brave.

Featuring New Georgia Project’s Stacey Abrams, Care.com’s Sheila Lirio Marcelo, Bankable Productions & SMiZE Cream’s Tyra Banks, MetricStream’s Shellye Archambeau, Moderna’s Stéphane Bancel, Digital Undivided’s Kathryn Finney, Ellevest’s Sallie Krawcheck, and American Express’s Ken Chenault.

Read a transcript of this episode: https://mastersofscale.com

Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.